Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for Immune Activation in Treated HIV (PROACTIV)
NCT06626555Phase 2Not yet recruiting
- Sponsor
- University College London
- Start
- Oct 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial in cytomegalovirus infection (CMV) comparing Letermovir with Standard of Care (2 arms). Primary endpoint: Change in activation in global CD8 T cells at 24 weeks. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06626555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06626555.